-
Mashup Score: 1Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL - 2 year(s) ago
The American College of Cardiology/American Heart Association/Multisociety cholesterol guidelines recommend adding a nonstatin if the low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL in patients with high-risk atherosclerotic cardiovascular disease ASCVD,1 effectively creating a target of
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4Genetic and functional evidence links a missense variant in B4GALT1 to lower LDL and fibrinogen - 2 year(s) ago
Exome sequencing identifies a genetic variant with protective effects in cardiovascular disease.
Source: ScienceCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 9Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL - 2 year(s) ago
The American College of Cardiology/American Heart Association/Multisociety cholesterol guidelines recommend adding a nonstatin if the low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL in patients with high-risk atherosclerotic cardiovascular disease ASCVD,1 effectively creating a target of
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3
This editorial refers to ‘Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial’, by K. Oyama et al., do
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 14Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol - PubMed - 3 year(s) ago
In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein subtilisin/kexin type 9 inhibition provides incremental clinical benefit only when lipoprotein(a) concentration is at least mildly elevated. (ODYSSEY Outcomes: Evaluation of Cardiovascula …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
Controversy over fat quality and cardiovascular disease risk stems from a series of meta-analyses of prospective cohort and randomised intervention trials, which found little evidence for a significant relationship between the intake of saturated fat and disease endpoints. Possible explanations for these null findings include difficulties inherent in estimating true food intake, the confounding…
Source: AtherosclerosisCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3
This study examined the performance of two novel low-density lipoprotein-cholesterol (LDL-C) calculations, LDLMartin and LDLSampson, on predicting atherosclerotic cardiovascular diseases (ASCVD) risk compared to traditional LDLFriedewald according to the 2018 American Heart Association/American College of Cardiology (AHA/ACC) primary prevention guidelines.
Source: AtherosclerosisCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 9Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease - 3 year(s) ago
Background:The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovas
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3
Switching from ATV to RSV was associated with a significant decrease in LDL-C among high-risk patients. Switching between these two high-intensity statins may offer a viable alternative to other treatment modifications aimed at lowering LDL-C in this population.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 7Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke - 3 year(s) ago
Background and Purpose— The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events
Source: StrokeCategories: Cardiologists, Latest HeadlinesTweet
No lowest limit to #LDLc #ApoB Cardiovascular Benefit Below 40 mg/dL | Circulation https://t.co/HHuTuan5pD